Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043171 · ClinicalTrials.gov registry record · Phase 1
Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2
A Phase 1 study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 238
- Enrollment target
NCT02043171 is a Phase 1 study that has completed, run by Metabolic Technologies. The registered enrollment target is 238 participants.
The verdict
NCT02043171, a Phase 1 study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 238 participants
- Enrollment target
Study Summary
Men and women lose muscle mass and strength with age. Loss of muscle mass and strength is accompanied by a loss of muscle function which can lead to diminished quality of life and more importantly can lead to serious fall requiring medical treatment. The investigators hypothesize that the combined supplements of Calcium-HMB and Vitamin D will lead to decreased falls and to improved quality of life (QOL) for older adults. The investigators further hypothesize that the addition of a modest exercise regimen to these supplements will enhance the synergistic effects of both Calcium-HMB and Vitamin D. Subjects will consume the dietary supplement 2 times per day for 12 months. Tests will consist of the following: a) strength of subjects' legs and elbow by Isokinetic Dynamometer; b) body composition; c) hand-grip strength by hand-grip dynamometer; d) functional mobility, balance and agility (Get-Up and Get-Up-and-Go tests); e) filling out questionnaires; and g) having blood drawn for biochemical measurements. Testing will be performed at the baseline (0 months) and at 3, 6, 9, and 12 months.
Interventions
- DIETARY_SUPPLEMENT Placebo
- BEHAVIORAL Exercise
- DRUG HMB plus Vitamin D
- BEHAVIORAL Non-Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043171
The ClinicalTrials.gov registry entry for NCT02043171 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02043171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043171 about?
NCT02043171 is a clinical study titled "Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2". Men and women lose muscle mass and strength with age. Loss of muscle mass and strength is accompanied by a loss of muscle function which can lead to diminished quality of life and more importantly can lead to serious fall requiring medical treatment. The investigators hypothesize that the combined s...
What is the current status of trial NCT02043171?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 238 participants. The study started on 2014-08. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02043171?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Exercise (BEHAVIORAL), HMB plus Vitamin D (DRUG), Non-Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT02043171?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.